DEF 14A: Coya Therapeutics Seeks Stockholder Approval for Equity Incentive Plan Amendment

Coya Therapeutics is asking stockholders to approve an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for issuance by 750,000, aiming to attract and retain key talent.

Summary

• Coya Therapeutics is holding its Annual Meeting of Stockholders on May 8, 2024, in a virtual format.
• Stockholders will vote on three proposals: electing two directors, amending the 2021 Equity Incentive Plan, and ratifying the appointment of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm.
• The key proposal involves amending the 2021 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance by 750,000 shares, bringing the total to 2,571,070 shares.
• The Board recommends voting FOR all three proposals.
• The company is providing access to proxy materials online to reduce costs and environmental impact.
• The Board met five times and acted by unanimous written consent nine times during the fiscal year ended December 31, 2023.
• The Audit Committee met five times and acted by unanimous written consent zero times during the fiscal year ended December 31, 2023.
• The Compensation Committee met one time and acted by unanimous written consent two times during the fiscal year ended December 31, 2023.
• The Nominating and Corporate Governance Committee met two times and acted by unanimous written consent one time during the fiscal year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The document is primarily procedural, outlining the agenda for the annual meeting and seeking approval for routine matters. The sentiment is neutral to slightly positive, as the company is taking steps to ensure it can attract and retain talent.

Positives

• The virtual format of the Annual Meeting allows for broader stockholder participation and reduces costs.
• The proposed amendment to the Equity Incentive Plan aims to attract and retain key talent by offering competitive equity-based compensation.
• The Board is actively engaged in risk oversight through its committees.
• The company has a Code of Business Conduct and Ethics in place.
• The company has entered into indemnification agreements with its directors and executive officers.

Negatives

• Increasing the number of shares available under the equity plan could dilute existing stockholders' ownership.
• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.
• On March 5, 2024, Dr. Ann Lee, a director, filed a late Form 4 reporting a purchase of our Common Stock made on August 22, 2023 by her spouses IRA.

Risks

• The company faces risks related to its financial condition, development and commercialization activities, operations, strategic direction, and intellectual property.
• The proxy statement contains forward-looking statements that are subject to various risks and uncertainties.
• Failure to secure stockholder approval for the Equity Incentive Plan amendment could hinder the company's ability to attract and retain talent.

Future Outlook

The company seeks to retain the services of eligible persons and to provide incentives for these persons to exert maximum efforts for the success of the Company.

Management Comments

• Our Board believes that the election of Dr. Villalobos and Dr. Goldstein, the amendment to our 2021 Incentive Plan to increase the number of the shares of common stock authorized for issuance thereunder, and the appointment of Weaver and Tidwell, L.L.P. as our independent registered public accounting firm for the year ending December 31, 2024 are advisable and in the best interests of the Company and its stockholders and recommends that you vote FOR Proposal 1, FOR Proposal 2, and FOR Proposal 3.

Industry Context

The company operates in the biotechnology industry, where equity compensation is a common practice to attract and retain talent.

Comparison to Industry Standards

• The Board reviewed market, industry and compensation peer group practices and data.
• The Board determined that the 2021 Incentive Plan does not provide sufficient share authorization to appropriately compensate our employees, non-employee directors and consultants for a duration comparable to that of the equity incentive plans of similarly situated companies.
• We believe the Plan Amendment Proposal will remedy this by both meeting our specific needs and positioning us to be in line with the equity incentive plan share authorization levels at similarly situated companies.

Related Party Transactions

• In connection with a financing in December 2020, we entered into a non-exclusive strategic advisory agreement with Allele Capital Partners LLC (Allele), a strategic advisory and investment firm, at $10,000 per month.
• In April 2022, we issued approximately $10.5 million in aggregate principal amount of convertible promissory notes.
• We have entered into indemnification agreements with each of our current directors and executive officers.

Stakeholder Impact

• Approval of the Equity Incentive Plan amendment could impact shareholders through potential dilution.
• The company's ability to attract and retain talent will impact employees and potentially customers and suppliers.
• The selection of an independent auditor impacts the credibility of financial reporting for all stakeholders.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on May 8, 2024.
• The company will publish final voting results in a Current Report on Form 8-K within four business days after the Annual Meeting.
• The Board will continue to evaluate its performance and the performance of its committees and individual directors on an annual basis.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, equity incentive plan, directors, compensation, corporate governance, Coya Therapeutics